1st Quarter - Report

TIBER CREEK GROUP for AMGEN INC

Firm
Client
Income
$80,000
Expenses
—

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Medicare/Medicaid MMM

Issues relating to Part D pricing reform. Issues relating to Part B pricing reform. S. 2543 - The Prescription Drug Price Reduction Act. H.R.3 - Lower Drug Costs Now Act of 2019. HR 6201 Families First Coronavirus Response Act (PL 116-27); CARES Act - S. 3548 (PL 116-136) - drug pricing issues, Part B home insfusion

LobbyistCovered position, as disclosed
JOHN MICHAEL GONZALEZ —
JAMES HEIMBACH —
JONATHON JONES —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 3 (116th), S. 2543 (116th), H.R. 6201 (116th), S. 3548 (116th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.